A Phase 1/2 interventional study of Exablate and Doxorubicin in Brain Tumor, sponsored by InSightec. Active, not recruiting at 1 site in Canada. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by InSightec · Phase 1/2, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Brain Neoplasms with a site in Canada — 23 open to participants now, 45 under way, 10 of them phase 3. Brain Neoplasms · Canada.
Among the 180 studies in Brain Neoplasms with a site in Canada, this one is the 145th largest by planned enrollment of the 161 interventional ones that give a count, is one of 4 that started in 2023, is one of 9 in phase 1/2, reaches primary completion later than 14 of the 44 other live ones, and was the 166th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →23 of the 180 studies in Brain Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Canada, United States, Belgium and 10 more countries
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–85
Rigel Pharmaceuticals · Sites in Canada, United States, Australia and 4 more countries
Ages 12–39
Nationwide Children's Hospital · Sites in Canada, United States, Australia and 3 more countries
Ages 12 mo–39 yrs
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: 5 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 62 · Phase 3 45
First in 1993; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Median enrollment 70 across the 161 interventional studies, 73 across the 16 observational. Of the 124 that completed or were terminated, 42 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 180 have an industry lead sponsor. The 10 most frequent:
InSightec is the lead sponsor of 84 studies on the registry; 9 are open to participants now.
InSightec has 7 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
16 of the studies in Brain Neoplasms with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06229483Phase 3Stephen LownieThe Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT03550391Phase 3Canadian Cancer Trials GroupStereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | 2027-06-30 |
| NCT03775330Sunnybrook Health Sciences CentreRadiosurgery With or Without Whole Brain Radiation for Multiple Metastases | 2026-12 |
| NCT01473485InSightecExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors | 2026-12 |
Add all 16 to your calendar (.ics) → With an account.
Among the 180 studies in Brain Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
This is a prospective, single arm, non-randomized feasibility study to evaluate the safety, feasibility and preliminary efficacy of Blood Brain Barrier Disruption (BBBD) using the Exablate Type 2 system in pediatric patients with Diffuse Intrinsic Pontine Gliomas (DIPG) undergoing Doxorubicin chemotherapy. The study will be conducted at a single center in Canada. Patients will undergo 3 treatment cycles, approximately 4 -6 weeks apart. The study aims to establish feasibility and safety of Exablate BBBD in conjunction with Doxorubicin in the treatment of pediatric DIPG and assess preliminary efficacy in this patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG
Device: Exablate · Drug: Doxorubicin
Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
Also known as: Exablate BBBD
Doxorubicin infusion
Also known as: Adriamycin, Rubex
Adverse Events
All adverse events from first treatment to end of study will be documented and reported according to the CTCAE terminology and severity scale
Time frame: 2 years
Blood Brain Barrier Disruption (BBBD)
BBBD will be assessed as a comparative ratio measured in pre and post-sonication contrast-enhanced MR images
Time frame: Immediately post BBBD sonication
Tumor Volume
Average volume of contrast-enhancement on post sonicated MRI scans will be compared with pre-sonicated scans
Time frame: Immediately post BBBD sonication
Progression Free Survival (PFS) and Overall Survival (OS)
PFS will be assessed based on the Response Assessment in Pediatric Neuro-Oncology (RAPNO) scale. Tumor related biomarkers will be compared before and after the BBBD procedure
Time frame: 2 years
Started Jan 2023 (actual). Primary completion is estimated for Jun 2026, 41 months after the start.
Of 72 phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 105. This study's planned 41 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxorubicin